Hostname: page-component-54dcc4c588-br6xx Total loading time: 0 Render date: 2025-09-30T10:42:36.179Z Has data issue: false hasContentIssue false
  • English
  • Français

Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study: commentary, Ophir

Published online by Cambridge University Press:  21 July 2025

Yaakov Ophir Open the ORCID record for Yaakov Ophir [Opens in a new window]
Yaakov Ophir*
Affiliation:
Department of Education, Ariel University, Ariel, Israel Centre for Human-Inspired Artificial Intelligence (CHIA), University of Cambridge, Cambridge, UK
*
Correspondence: Yaakov Ophir. Email: yaakovophir@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Attention-deficit hyperactivity disorderpremature mortalityattention-deficit hyperactivity disorder medicationsstimulant medicationstreatment of choice

Information

Type
Commentary
Information
The British Journal of Psychiatry , Volume 227 , Issue 3 , September 2025 , pp. 648 - 649
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Royal College of Psychiatrists

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

O’Nions, E, El Baou, C, John, A, Lewer, D, Mandy, W, McKechnie, DGJ et al. Life expectancy and years of life lost for adults with diagnosed ADHD in the UK: matched cohort study. Br J Psychiatry [Epub ahead of print] 23 January 2025. Available from: https://doi.org/10.1192/bjp.2024.199.Google Scholar
Nigg, JT Attention-deficit/hyperactivity disorder and adverse health outcomes. Clin Psychol Rev 2013; 33: 215–28.CrossRefGoogle ScholarPubMed
Gould, MS, Walsh, BT, Munfakh, JL, Kleinman, M, Duan, N, Olfson, M et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009; 166: 992–1001.CrossRefGoogle ScholarPubMed
Schelleman, H, Bilker, WB, Kimmel, SE, Daniel, GW, Newcomb, C, Guevara, JP et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry 2012; 169: 178–85.CrossRefGoogle ScholarPubMed
Mosholder, AD, Taylor, L, Mannheim, G, Ortendahl, L, Woodworth, TS, Toh, S. Incidence of heart failure and cardiomyopathy following initiation of medications for attention-deficit/Hyperactivity disorder: a descriptive study. J Clin Psychopharmacol 2018; 38: 505–8.CrossRefGoogle ScholarPubMed
Ophir, Y ADHD is Not an Illness and Ritalin is Not a Cure: A Comprehensive Rebuttal of the (Alleged) Scientific Consensus. World Scientific, 2022.CrossRefGoogle Scholar
Shoval, G, Visoki, E, Moore, TM, DiDomenico, GE, Argabright, ST, Huffnagle, NJ et al. Evaluation of attention-deficit/hyperactivity disorder medications, externalizing symptoms, and suicidality in children. JAMA Netw Open 2021; 4: e2111342.CrossRefGoogle ScholarPubMed
Bruno, S, Kiki, C, Katia, V. General practice database on mortality in adults on methylphenidate: cohort study. BMJ Open 2022; 12: e057303.Google Scholar
McKechnie, DGJ, O’Nions, E, Dunsmuir, S, Petersen, I. Attention-deficit hyperactivity disorder diagnoses and prescriptions in UK primary care, 2000–2018: population-based cohort study. BJPsych Open 2023; 9: e121.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.